Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Highlights of This Issue

DOI:  Published December 2011
  • Article
  • Info & Metrics
  • PDF
Loading

Akt/mTOR Pathway Induces Resistance to Cixutumumab

Shin et al. Page 2437

Insulin-like growth factor receptor (IGF-1R)-targeted monoclonal antibodies (mAb) have shown limited anticancer therapeutic efficacy. In this study, Shin and colleagues investigated the mechanisms of resistance to a fully humanized anti-IGF-1R mAb cixutumumab in head and neck squamous cell carcinoma (HNSCC). They found that resistance to IGF-1R inhibition by cixutumumab was associated with Akt/mammalian target of rapamycin (mTOR)-mediated de novo protein synthesis of EGFR, Akt1, and survivin and activation of the EGFR pathway, and cotargeting IGF-1R/mTOR had synergistic antitumor effects in vitro and in vivo. These results show potential clinical use of cotargeting IGF-1R and Akt/mTOR in patients with HNSCC.

Promise of Dual Energy Metabolic Pathway Targeted Therapy

Cheong et al. Page 2350

Cellular bioenergetics is an emerging therapeutic target in cancer. Despite the Warburg effect playing a critical role in providing bioenergetics to tumor cells, inhibition of glycolysis alone showed limited efficacy in clinical trials. Cheong and colleagues show that activation of AMPK as a consequence of decreased glycolysis increases transcription of genes in cellular respiration, thereby bypassing the effect of decreased glycolysis. Dual inhibition of both glycolysis with glycolysis inhibitor 2-deoxyglucose and oxidative phosphorylation with metformin leads to marked decrease in ATP and cell death, which is sufficient to suppress tumor growth in vivo. This combination could be readily and rapidly translated to the clinic.

AZD1480 Inhibits Growth and Prolongs Survival in Glioblastoma

McFarland et al. Page 2384

The JAK/STAT pathway has been linked to multiple cancers including glioblastoma (GBM). McFarland and colleagues tested the therapeutic potential of AZD1480, a newly developed JAK1/2 inhibitor in GBM. Patient-derived human GBM xenografts serially maintained in the flanks of nude mice were profiled and chosen for the study based on high JAK/STAT-3 activation. AZD1480 treatment inhibited the growth of the xenograft flank tumors and prolonged survival in an orthotopic model, which was attributed to decreased STAT-3 signaling. AZD1480 may potentially be an effective antitumor agent when combined with current therapies available for GBM.

Dual Targeting of PI3K and mTOR in Cancer

Wallin et al. Page 2426

The phosphoinositide-3 kinase (PI3K)/Akt signaling pathway is fundamental to numerous cellular processes. Abnormal activation of the pathway has been implicated in many cancers and therefore represents an attractive target for therapeutic intervention. GDC-0980 is a potent and selective inhibitor of Class I PI3K and mTOR kinase (TORC1/2) with excellent pharmacokinetic and pharmaceutical properties. Wallin and colleagues report that GDC-0980 potently inhibits xenograft growth of various malignancies and the effects on tumor growth correlate with changes in pharmacodynamic biomarkers. Thus, GDC-0980 is a promising therapeutic candidate for clinical cancer development.

  • ©2011 American Association for Cancer Research.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 10 (12)
December 2011
Volume 10, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Highlights of This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Highlights of This Issue
Mol Cancer Ther December 1 2011 (10) (12) 2213;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Highlights of This Issue
Mol Cancer Ther December 1 2011 (10) (12) 2213;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Akt/mTOR Pathway Induces Resistance to Cixutumumab
    • Promise of Dual Energy Metabolic Pathway Targeted Therapy
    • AZD1480 Inhibits Growth and Prolongs Survival in Glioblastoma
    • Dual Targeting of PI3K and mTOR in Cancer
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement